Jatin J. Shah

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Shaji Kumar, J H Lee, Juan José Lahuerta et al. · Leukemia · 2011 · 721 citations

Medicine, Hematology, Pharmacotherapy +15

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou et al. · New England Journal of Medicine · 2019 · 673 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement

Meletios Α. Dimopoulos, Jens Hillengaß, Saad Z. Usmani et al. · Journal of Clinical Oncology · 2015 · 394 citations · Full text

Medicine, Hematology, Radiology +17

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo et al. · The Lancet Haematology · 2020 · 337 citations · Full text

Medicine, Hematology, Oncology +11

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Sebastian Grosicki, Maryana Simonova, Ivan Špıčka et al. · The Lancet · 2020 · 324 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16